Previous studies have reported that the probability of lung recurrence in patients with early breast cancer with hormone receptor (HR)‐positive human epidermal growth factor receptor 2 (HER2)‐positive and triple‐negative subtypes was higher than HR‐positive HER2‐negative tumors 6, 7, 8, 9, 10, 11. This evidence concerns the gene ERBB2 and breast carcinoma.